Figure 1Distribution in results of the AxSYM avidity index and BED-capture enzyme immunoassay by human immunodeficiency virus seroconverters.
Table 1Characteristics of HIV seroconverters (N = 81) in South Korea.a
|
Number of persons (%) |
Sex |
Male |
77 (95.1) |
Female |
4 (4.9) |
Age (y) |
<20 |
4 (4.9) |
20–29 |
26 (32.1) |
30–39 |
21 (25.9) |
40–49 |
15 (18.5) |
≥50 |
14 (17.3) |
Unknown |
1 (1.2) |
Year |
2005–2006 |
15 (18.5) |
2007–2008 |
17 (21.0) |
2009–2010 |
23 (28.4) |
2011–2012 |
26 (32.1) |
Stage |
Eclipse phase (10 d) |
– |
I (17 d) |
2 (2.5) |
II (22 d) |
33 (40.7) |
III (25 d) |
6 (7.4) |
IV (31 d) |
38 (46.9) |
V (101 d) |
2 (2.5) |
VI (open-ended) |
– |
Initial CD4+cell countb
|
< 200 |
8 (16.7) |
200–349 |
13 (27.1) |
350–499 |
17 (35.4) |
≥500 |
11 (22.9) |
Table 2Mean recency period at the AxSYM avidity assay and BED-capture enzyme immunoassay.
Assay |
Cutoff value |
Mean recency period (d) |
95% CI |
Avidity |
0.8 |
158 |
135 |
181 |
BED-CEIA |
0.8 |
189 |
170 |
208 |
Table 3Use of different recency periods of the AxSYM avidity assay and BED-capture enzyme immunoassay to identify recent human immunodeficiency virus infections.
Recency period (d) |
Avidity assay
|
BED-CEIA
|
Sensitivity (%) |
Specificity (%) |
Sensitivity (%) |
Specificity (%) |
120 |
82.0 |
86.2 |
79.5 |
80.8 |
130 |
86.5 |
75.9 |
84.8 |
76.9 |
140 |
91.0 |
69.0 |
88.9 |
69.2 |
150 |
92.5 |
69.0 |
90.1 |
65.4 |
160 |
93.2 |
58.6 |
92.4 |
65.4 |
170 |
95.5 |
55.2 |
94.2 |
61.5 |
180 |
96.2 |
55.2 |
94.7 |
57.7 |
190 |
97.0 |
51.7 |
96.5 |
57.7 |
200 |
97.7 |
51.7 |
97.7 |
57.7 |
210 |
97.7 |
48.3 |
97.7 |
53.8 |
220 |
97.7 |
44.8 |
98.2 |
50.0 |
230 |
98.5 |
44.8 |
98.8 |
50.0 |